MBio Diagnostics Announces Rebrand to LightDeck Diagnostics to Reflect Commitment to Its Innovative Waveguide Product Platform
By: Colorado BioScience Association Date: 10/21/2020
Supporting the advancement of its mission to transform diagnostics, the company also welcomes new members and names a new Chairman to its Board of Directors
October 16, 2020 Boulder, CO — MBio Diagnostics, the company taking the point-of-care anywhere with on-the-spot, central lab-quality diagnostics, announced today that it is changing its corporate name to LightDeck Diagnostics. The name change reflects the company’s commitment to its proprietary LightDeck® platform and its pivotal role in shaping the future of healthcare and diagnostic testing more broadly. In tandem, the company announces changes to its Board of Directors, including the appointment of Michael Chang, Judith O’Brien, JD, and elevation of Robert J. Silverman to Chairman of the Board.
The company’s proprietary LightDeck® platform combines an advanced laser waveguide with novel materials and patented, low-cost manufacturing techniques to deliver lab-quality results anywhere, in minutes. The platform, which leverages a precise, but little-known laser technology called a planar waveguide, has demonstrated success across veterinary diagnostics and environmental testing, and offers significant potential across a wide range of clinical applications, including COVID-19, cardiac, acute care, sepsis and more. The technology is mature and versatile, allowing LightDeck to spin up new, extended applications on a single platform within just months, versus traditional systems which can take years or are limited to only one test.
“Our new name, LightDeck Diagnostics, allows us to emphasize the central nature of our LightDeck platform in all of our work, and its critical role in our mission to transform diagnostics by broadening access, increasing speed, lowering costs and improving quality,” said CEO and founder Chris Myatt. At LightDeck, we are committed to delivering breakthrough products and services that will help usher in a future where the point-of-care is truly anywhere.””
LightDeck welcomes Michael Chang and Judith O’Brien, JD to its Board of Directors. Mr. Chang is an experienced entrepreneur and current CEO of YesVideo, and brings deep strategic expertise and fund-raising experience to LightDeck’s board. Ms. O’Brien, who has served for over twenty years as a director of numerous public and private companies, brings extensive experience in strategic relationships, financing, compensation, corporate governance and risk management to the LightDeck team. Robert J. Silverman, a director and strategic advisor to LightDeck since 2013, will sit as Chairman of the Board.
“I am honored to be named Chairman of LightDeck’s Board of Directors at this exciting inflection point in the company’s evolution,” remarked Mr. Silverman. “LightDeck’s revolutionary planar waveguide technology has the potential to drive a near-term transformation in diagnostics for COVID-19 testing and longer-term across a wide range of clinical applications. I look forward to playing a more significant role in helping the company realize the full potential of this innovation.”
In July 2020, MBio Diagnostics merged with Brava Diagnostics and the combined companies formed LightDeck Diagnostics. The merger brings together a team of clinical diagnostic and laser optic veterans who have worked across life sciences and photonics companies such as Bayer Diagnostics, Abbott, Siemens, and others. Together, with the guidance from its board, LightDeck moves to bring quick and accurate diagnostic tests wherever and whenever they are needed, without compromise.
About LightDeck Diagnostics
LightDeck Diagnostics believes in a new approach to healthcare, where fast, accurate, simple, low-cost diagnostic tests will be run wherever and whenever they are needed, without compromise. The company’s proprietary LightDeck® platform combines an advanced laser waveguide with novel materials and patented manufacturing techniques to deliver lab-quality results anywhere, in minutes. LightDeck is introducing a portfolio of in vitro diagnostic panels, the first is an on-the-spot test for COVID-19. The LightDeck platform is currently commercialized in veterinary diagnostics and for environmental testing. Learn more at www.LightDeckDx.com